140 related articles for article (PubMed ID: 37467961)
21. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G
Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335
[TBL] [Abstract][Full Text] [Related]
22. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
[TBL] [Abstract][Full Text] [Related]
23. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors, valproic acid and trichostatin-A induce apoptosis and affect acetylation status of p53 in ERG-positive prostate cancer cells.
Fortson WS; Kayarthodi S; Fujimura Y; Xu H; Matthews R; Grizzle WE; Rao VN; Bhat GK; Reddy ES
Int J Oncol; 2011 Jul; 39(1):111-9. PubMed ID: 21519790
[TBL] [Abstract][Full Text] [Related]
25. Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities.
Zhao N; Yang F; Han L; Qu Y; Ge D; Zhang H
Molecules; 2020 Feb; 25(3):. PubMed ID: 32046013
[TBL] [Abstract][Full Text] [Related]
26. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
27. Curbing autophagy and histone deacetylases to kill cancer cells.
Gammoh N; Marks PA; Jiang X
Autophagy; 2012 Oct; 8(10):1521-2. PubMed ID: 22894919
[TBL] [Abstract][Full Text] [Related]
28. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
[TBL] [Abstract][Full Text] [Related]
29. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.
Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A
Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592
[TBL] [Abstract][Full Text] [Related]
30. 4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation.
Mahal K; Kahlen P; Biersack B; Schobert R
Exp Cell Res; 2015 Aug; 336(2):263-75. PubMed ID: 26101158
[TBL] [Abstract][Full Text] [Related]
31. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
32. Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia.
Sun X; Hasanali ZS; Chen A; Zhang D; Liu X; Wang HG; Feith DJ; Loughran TP; Xu K
Br J Haematol; 2015 Feb; 168(3):371-83. PubMed ID: 25284154
[TBL] [Abstract][Full Text] [Related]
33. Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
Yang W; Li L; Ji X; Wu X; Su M; Sheng L; Zang Y; Li J; Liu H
Bioorg Med Chem; 2014 Nov; 22(21):6146-55. PubMed ID: 25261927
[TBL] [Abstract][Full Text] [Related]
34. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells.
Francisco R; Pérez-Perarnau A; Cortés C; Gil J; Tauler A; Ambrosio S
Cancer Lett; 2012 May; 318(1):42-52. PubMed ID: 22186300
[TBL] [Abstract][Full Text] [Related]
35. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses.
Bolden JE; Shi W; Jankowski K; Kan CY; Cluse L; Martin BP; MacKenzie KL; Smyth GK; Johnstone RW
Cell Death Dis; 2013 Feb; 4(2):e519. PubMed ID: 23449455
[TBL] [Abstract][Full Text] [Related]
36. Differential sensitivity of human leukemic cell lines to the histone deacetylase inhibitor, trichostatin A.
Ninios YP; Sekeri-Pataryas KE; Sourlingas TG
Leuk Res; 2010 Jun; 34(6):786-92. PubMed ID: 19782399
[TBL] [Abstract][Full Text] [Related]
37. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
[TBL] [Abstract][Full Text] [Related]
38. Ginsenoside 20(s)-Rh2 as potent natural histone deacetylase inhibitors suppressing the growth of human leukemia cells.
Liu ZH; Li J; Xia J; Jiang R; Zuo GW; Li XP; Chen Y; Xiong W; Chen DL
Chem Biol Interact; 2015 Dec; 242():227-34. PubMed ID: 26482938
[TBL] [Abstract][Full Text] [Related]
39. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
40. CaMKII exacerbates heart failure progression by activating class I HDACs.
Zhang M; Yang X; Zimmerman RJ; Wang Q; Ross MA; Granger JM; Luczak ED; Bedja D; Jiang H; Feng N
J Mol Cell Cardiol; 2020 Dec; 149():73-81. PubMed ID: 32971072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
